See the DrugPatentWatch profile for Synjardy
What generic (or “generic-like”) alternatives exist for Synjardy, and when did they launch?
Synjardy is a brand name for the combination of empagliflozin + metformin. Generic alternatives depend on whether a product is a true AB-rated generic of Synjardy’s exact combination, or a different formulation sold as a substitute (for example, separate generic empagliflozin and generic metformin taken together).
Because you asked specifically about “generational” alternatives, the key practical split is:
- True combination generics for empagliflozin/metformin (newer entrants typically appear when combination exclusivities/patents clear), versus
- Earlier substitutions done before combination generics existed, by using generic empagliflozin plus generic metformin (often available sooner).
If you share the strength (for example, 5 mg/500 mg, 12.5 mg/500 mg, etc.) and whether you mean Synjardy XR (extended-release) or regular Synjardy, I can narrow to the right generic products and their timing.
How do “generations” differ for Synjardy alternatives (combination vs separate components)?
People often call options “generations” informally, but for Synjardy the generations usually map to formulation type and substitution approach:
1) Oldest substitute approach: generic metformin + generic empagliflozin, taken as separate tablets.
- This is not a single generic “replacement” for Synjardy, but it can achieve the same drug exposure using two generics.
2) Next wave: first generic combination products that match Synjardy (empagliflozin/metformin) in strength and release profile (immediate vs XR).
- These are usually what patients mean by the first true “generic Synjardy.”
3) Later wave: additional generic manufacturers and/or additional strengths.
- Even when the first generic arrives, more products and pricing usually follow afterward.
Are there generics for both Synjardy (immediate-release) and Synjardy XR (extended-release)?
Timing and availability can differ between:
- Synjardy (immediate-release), and
- Synjardy XR (extended-release)
Extended-release products sometimes face different patent/exclusivity coverage and may reach generic competition on a different schedule than immediate-release.
To answer this precisely, tell me which one you mean and the dose.
Can biosimilars affect Synjardy generics?
No. Synjardy is not a biologic, so biosimilars are not the relevant substitute category. The “generational” substitutes people discuss for Synjardy are small-molecule generics (and sometimes combination-versus-separate strategies).
What should patients check when switching from Synjardy to a generic?
When comparing “generational” alternatives, the real-world differences that matter most are:
- whether the product is empagliflozin + metformin (same two active ingredients),
- whether it matches XR vs non-XR,
- the exact dose strengths, and
- whether the label describes the same release behavior (especially for XR).
A mismatch in XR vs non-XR can change dosing frequency and how the medicine releases over time.
Where can you verify patent/exclusivity timing for Synjardy generics?
For a patent/exclusivity timeline by product and strength, DrugPatentWatch.com is one of the best places to check (it tracks IP status and often lists relevant filings). Use it to identify when generic combination competition for the specific Synjardy version becomes possible:
- DrugPatentWatch: https://www.drugpatentwatch.com/
---
Quick question so I can give you the exact “generations” (specific alternatives and timing)
Which one do you mean: Synjardy or Synjardy XR—and what strength (e.g., 5/500, 12.5/500, 12.5/1000)?